<DOC>
	<DOCNO>NCT01617070</DOCNO>
	<brief_summary>This study examine effect tetrahydrobiopterin ( Kuvan ) Large Neutral Amino Acid ( LNAA ) therapy melatonin dopamine level individual Phenylketonuria ( PKU ) . The investigator hypothesize Kuvan therapy improve melatonin secretion urine dopamine level extent . However significantly great response melatonin dopamine secretion may observe combined treatment Kuvan supplementation LNAA .</brief_summary>
	<brief_title>Effects Kuvan Melatonin Secretion</brief_title>
	<detailed_description>Background : Phenylketonuria ( PKU ) genetic condition due miss one key enzymes phenylalanine ( Phe ) degradation . The miss enzyme phenylalanine hydroxylase ( PAH ) . Because deficiency enzyme , plasma Phe highly elevate compare plasma amino acid . This abnormal ratio i.e. , Phe vs. large neutral amino acid ( LNAA ) transport brain precursor neurotransmitter common transporter LAT1 , likely contribute neurotransmitter deficiency individual PKU . Patients restrict Phe intake develop mental retardation neuropsychological disorder . Treatment PKU historically limit restriction Phe intake , mean protein restriction . The FDA recently approve new medication , Kuvan , synthetic form tetrahydrobiopterin ( BH4 ) manufacture BioMarin Pharmaceutical Inc. , patient PKU . Kuvan cofactor PAH , tyrosine hydroxylase , tryptophan hydroxylase . Patients PKU typically undergo month-long trial Kuvan determine responder drug , mean blood phenylalanine drop 30 percent . Those responder usually continue Kuvan , however recent study ( HS 08-00147 ) show classical PKU patient Kuvan responder demonstrate improvement maladaptive behavior , suggest effect Kuvan CNS system without reduce blood phenylalanine concentration ( Moseley et al , manuscript preparation ) . Seven subject respond Kuvan low blood Phe level significant increase blood tyrosine 6 month ( p=0.015 ) , along improvement Vineland Internalizing Overall Maladaptive Behavior Indexes 12 month ( p=0.032 0.049 , respectively ) . Kaufman report Kuvan dose 20 mg/kg/day increase CSF BH4 level ( 1 ) . Based observation , likely Kuvan effect neurotransmitter metabolism . Supplementation large neutral amino acid ( LNAA ) medical food use Europe past 25 year believe effective treating patient PKU . In article Shindeler et al . ( 2 ) , 16 individual ( 7 male 9 female ; age 11y 45 ) participate study consist 4 week wash-out 4 two-weeks stage ( phenylalanine restrict diet with/without LNAA , phenylalanine restrict diet with/without LNAA ) . No specific adverse effect report article . Large neutral amino acid therapy treatment PKU do past ( 3 ) . LNAA use primarily adolescent adult adhere standard phe-restricted diet . LNAA treatment approve PKU patient like special formula . Our previous study demonstrate deficiency serotonin brain , evidence low nocturnal melatonin secretion reduce urine dopamine compare control , supplementation LNAA improve , normalize marker . Rationale : Patients PKU think deficient tyrosine tryptophan brain tissue level abnormal phe/tyrosine phe/tryptophan ratio . Previous study show low serotonin level cerebrospinal fluid PKU individual improvement observe tryptophan supplementation ( 4 ) . Our prior study suggest deficiency tryptophan brain tissue demonstrate low nocturnal melatonin secretion 6-sulfatoxymelatonin , stable metabolite melatonin ( 5 ) . LNAA supplementation result improvement melatonin secretion , however , melatonin secretion patient PKU LNAA still significantly low control group . Supplementation Kuvan may activate brain tyrosine tryptophan hydroxylases ( 6 ) , result improvement nocturnal melatonin secretion urine melatonin dopamine concentration . By supplement LNAA increase amount neurotransmitter precursor amino acid transport brain activate brain tyrosine tryptophan hydroxylases Kuvan act precursor produce neurotransmitter , i.e. , serotonin dopamine . These synergistic effect may increase melatonin dopamine level closer control level . Aims Study : To show scientific evidence improvement metabolism neurotransmitter include serotonin dopamine patient PKU treat LNAA , Kuvan , Kuvan LNAA . Objectives : This investigator initiate study three objective : ( 1 ) To evaluate tetrahydrobiopterin ( Kuvan ) supplementation beneficial effect melatonin secretion urine dopamine level individual PKU treat large neutral amino acid ; ( 2 ) To demonstrate synergistic effect LNAA supplementation Kuvan therapy improvement neurotransmitter metabolism individual PKU ; ( 3 ) To gather pilot information necessary design large , multicenter trial intervention , result pilot study indicate study warrant . Study Methodology : This study conduct adult patient PKU four 4-week phase : phase I ( large neutral amino acid/LNAA ) , phase II ( Washout ) , phase III ( Kuvan ) phase IV ( Kuvan LNAA ) . Kuvan supplementation adjust provide 20 mg/kg/day . LNAA therapy adjust manufacturer 's instruction ( total tablet LNAA 1/2 X BW kg ) . On last day phase , subject stay approximately 14 18 hour overnight CTU USC University Hospital . Blood specimen collect every 2 hour 7:00 pm 7:00 . First void urine collect day discharge ( patient ask void urine 11:00 pm first void urine collect ) . Blood collect red top tube ( 5 ml ) IV line saline lock study period . Avoid hemolysis collect blood IV line reasonably large peripheral vein . Blood leave clot 45 minute room temperature ( 18-28 C ) protect light ( dim flash light yellow light &lt; 100 lux ) . Serum collect store - 20 C subject analysis plasma melatonin plasma amino acid . Urine 20 ml first void sample collect two plain tube ( 10 ml per tube ) store deep freezer ( -20 C ) subject analyzed dopamine 6-sulfatoxymelatonin . This open-labeled study . During four 4-week phase , subject remain protein-restricted diet . LNAA tablet consider medicine , category medical food ; example include low protein food . LNAA tablet provide LNAA manufacture ( Applied Nutrition ) . Kuvan take per orally breakfast LNAA tablet take meal three time per day .</detailed_description>
	<mesh_term>Phenylketonurias</mesh_term>
	<mesh_term>Serotonin</mesh_term>
	<mesh_term>Melatonin</mesh_term>
	<criteria>Adult Englishspeaking patient confirm PKU , tolerate Kuvan therapy 20 mg/kg/day past , currently LNAA supplement consider candidate study . Subjects must able stop LNAA therapy 4 week . This determined subject , base past personal experience . Individuals never take Kuvan , never LNAA therapy , age 18 , speak English exclude . Subjects stop LNAA therapy 4 week exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Tetrahydrobiopterin</keyword>
	<keyword>Kuvan</keyword>
	<keyword>Phenylketonuria ( PKU )</keyword>
	<keyword>Large Neutral Amino Acids</keyword>
	<keyword>Serotonin</keyword>
	<keyword>Dopamine</keyword>
	<keyword>Melatonin</keyword>
</DOC>